The Experience of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms Abstract #764

Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a Neuroendocrine Tumor Board established at our University Hospital.
Aim(s):
Materials and methods: According to the indications for ENETS Centers of Excellence, meetings with experts in Endocrinology, Endoscopy, Nuclear Medicine, Oncology, Pathology, Radiology and Surgery are held; interactive computer-assisted presentation of three or four cases each time presented by one representative of the caring equipe; electronic reports written, circulated and stored; descriptive statistics for data analysis.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Laura De Marinis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#542 Establishment of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms
Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a neuroendocrine tumor board (TB) established at our University Hospital.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#765 Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors
Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Laura De Marinis
Keywords: everolimus, prrt
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#2137 Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers
Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Wouter Zandee
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...